Jazz Pharmaceuticals posts $215 million in net income for third quarter
The company’s high-profile cannabis-based drug, Epidiolex, accounted for $251.5 million in revenue for the quarter.
The post Jazz Pharmaceuticals posts $215 million in net income for third quarter appeared first on Green Market Report.
